Andrographolide

Andrographolide (C₂₀H₃₀O₅) is a bicyclic diterpenoid lactone that exerts anti-inflammatory and immunomodulatory effects primarily through inhibition of NF-κB signaling, suppression of TNF-α and IL-12 production, and blockade of ERK1/2 and PI3K/Akt pathways. In a Phase I dose-escalating clinical trial in HIV-positive patients, andrographolide supplementation produced a statistically significant rise in mean CD4⁺ lymphocyte counts, and in vitro exposure at 1 µM increased human peripheral blood lymphocyte proliferation by 14% via IL-2 induction.

Origin & History

Andrographolide is the principal bioactive diterpenoid lactone isolated from Andrographis paniculata, an annual herbaceous plant native to South and Southeast Asia, particularly India, Sri Lanka, and China. The plant thrives in tropical and subtropical climates with well-drained soils and is widely cultivated across India, Thailand, and Malaysia for medicinal purposes. Andrographolide concentrations in the plant vary significantly by part and growing condition, reaching 0.5–6% in dried leaves, 0.8–1.2% in stems, and approximately 4% in the dried whole plant.

Historical & Cultural Context

Andrographis paniculata, the source plant of andrographolide, has been used for over two millennia in Ayurvedic medicine under the name 'kalmegh' (meaning 'king of bitters') and in Siddha medicine, where it was prescribed as a bitter tonic, antipyretic, and liver-protective agent for fevers, jaundice, dysentery, and respiratory infections. In Traditional Chinese Medicine it is known as 'Chuanxinlian' and has been listed in the Chinese Pharmacopoeia, prescribed as a heat-clearing and detoxifying herb for infections, sore throat, and diarrhea, with significant use during the 1970s Chinese campaigns against influenza and bacterial dysentery. The isolated compound andrographolide was first characterized chemically in the mid-20th century, with its diterpenoid lactone structure elucidated through X-ray crystallography, enabling targeted pharmacological investigation separate from the whole-plant preparations used traditionally. The plant's extreme bitterness — attributed largely to andrographolide and its analogues — led to its Sanskrit epithet 'Maha-tikta' (the great bitter), and traditional preparations included fresh juice, powders, and decoctions prepared from aerial parts harvested before flowering to maximize diterpenoid content.

Health Benefits

- **Anti-Inflammatory Activity**: Andrographolide inhibits NF-κB nuclear translocation and suppresses downstream pro-inflammatory cytokines TNF-α and IL-12, reducing neutrophil oxygen radical production and macrophage migration in preclinical models.
- **Immunomodulation**: At 1 µM, andrographolide induces IL-2 secretion in human peripheral blood lymphocytes, increasing cell proliferation by 14%, with potential applications in immune-compromised conditions including HIV infection.
- **Hepatoprotection**: Preclinical studies consistently demonstrate andrographolide's ability to protect hepatocytes against chemical-induced injury through antioxidant mechanisms and suppression of inflammatory signaling, supporting its long-standing traditional use in liver disorders.
- **Antioxidant Effects**: Purified andrographolide demonstrates an IC₅₀ of 3.2 mg/mL for DPPH free radical scavenging, substantially outperforming crude plant extracts (IC₅₀ ~220.5 mg/mL), with total free radical scavenging in standardized extracts ranging from 77.66–89.28%.
- **Anticancer Potential (Preclinical)**: Andrographolide exhibits cytotoxic activity against colorectal cancer cells (CACO-2) with an IC₅₀ of 32.46 µg/mL in vitro, likely mediated through NF-κB inhibition and disruption of cell cycle progression.
- **Antihypertensive Effects**: In vitro studies report up to 94% inhibition of angiotensin-converting enzyme (ACE) activity by andrographolide-rich fractions, suggesting a mechanism relevant to blood pressure regulation that warrants clinical investigation.
- **Anti-HIV Activity**: Andrographolide demonstrated an EC₅₀ of 49 µg/mL against HIV replication in vitro, and a Phase I trial reported significant CD4⁺ lymphocyte elevation attributed to inhibition of HIV-induced cell cycle dysregulation.

How It Works

Andrographolide's primary anti-inflammatory mechanism involves covalent interaction with cysteine residues on IκB kinase β (IKKβ), preventing phosphorylation and degradation of IκBα and thereby blocking NF-κB nuclear translocation and transcription of pro-inflammatory genes including TNF-α, IL-1β, and IL-12. It concurrently inhibits protein kinase C, ERK1/2 MAPK, and PI3K/Akt signaling cascades, collectively attenuating oxidative burst in neutrophils and chemotactic migration of macrophages. At low concentrations (1 µM), andrographolide upregulates IL-2 gene expression in T-lymphocytes, promoting lymphocyte proliferation and adaptive immune responses, while at higher concentrations cytotoxic effects predominate, suggesting a biphasic immunomodulatory profile. The compound's lactone moiety is essential for its bioactivity, forming Michael adducts with thiol groups on target proteins, and semi-synthetic analogues such as 14-deoxy-11,12-didehydroandrographolide exhibit enhanced immunostimulatory and anti-infective activities relative to the parent molecule.

Scientific Research

The evidentiary base for andrographolide consists predominantly of in vitro cell culture studies and animal pharmacology experiments, with only limited human clinical data available; this places overall evidence strength in the preliminary-to-moderate range. A Phase I dose-escalating trial in HIV-positive individuals reported significant increases in mean CD4⁺ lymphocyte counts following andrographolide administration, providing the most direct human efficacy signal, though sample sizes and precise effect magnitudes were not fully detailed in available reports. Pharmacokinetic studies in humans have characterized oral bioavailability following a 200 mg dose, yielding a C_max of 58.62 ng/mL at 1.6 hours and a half-life of 10.50 hours, which provides a rational basis for dosing interval selection. Optimized formulations (liquid-filled and pellet-based) have demonstrated dramatically improved in vitro dissolution (97.64–97.74% within 15 minutes versus 10% over 2 hours for crude extract), though whether this translates to proportional clinical benefit in controlled trials has not yet been established.

Clinical Summary

The most clinically informative human data for andrographolide comes from a Phase I dose-escalating trial in HIV-positive patients, where the compound produced a statistically significant rise in CD4⁺ lymphocyte levels, suggesting biological activity at doses tolerated in humans. Human pharmacokinetic data from a 200 mg oral dose study established a C_max of 58.62 ng/mL at Tmax 1.6 hours and a terminal half-life of 10.50 hours, supporting twice-daily dosing intervals. In vitro human lymphocyte studies found that 1 µM andrographolide increased HPBL proliferation by 14% and induced IL-2, providing mechanistic corroboration of the immune-enhancing signal seen clinically. Overall, clinical evidence remains limited to early-phase trials and cell-based human studies; well-powered Phase II/III randomized controlled trials are needed before efficacy claims can be made with high confidence for any indication.

Nutritional Profile

Andrographolide itself is a pure diterpenoid lactone compound (C₂₀H₃₀O₅, MW 350.45 g/mol) with no direct macronutrient contribution; in the context of whole Andrographis paniculata plant material, the nutritional profile includes the following bioactive constituents: andrographolide at 0.5–6% in dried leaves and up to 14.47% in optimized aerial part extracts; neoandrographolide at up to 110.77 mg/g in optimized methanolic fractions; 14-deoxy-11,12-didehydroandrographolide at up to 49.19 mg/g; andrograpanin at up to 17.39 mg/g; and flavonoids including myricetin at approximately 0.3190% in stem extracts. Over 20 distinct diterpenoids and flavonoids have been identified across plant parts. Bioavailability of andrographolide is critically limited by its lipophilicity and first-pass hepatic metabolism, with absolute oral bioavailability of approximately 1.19% in rodent models, though enhanced formulations can dramatically improve dissolution and presumptive absorption.

Preparation & Dosage

- **Standardized Extract (oral capsule/tablet)**: Most commercial products are standardized to 10–30% andrographolide content; typical doses used in preclinical efficacy studies translate to ~100–400 mg extract daily in adults, though no universally accepted human therapeutic dose has been established.
- **Purified Andrographolide (research/Phase I)**: Oral doses studied in humans include 200 mg as a single dose for pharmacokinetic profiling; escalating doses were used in the HIV Phase I trial without specified upper limits in available reports.
- **Animal Study Reference Doses**: 50–100 mg/kg body weight in rats achieved plasma C_max of ~1 µM at 30 minutes, with absolute oral bioavailability of only 1.19%, underscoring that human-equivalent doses require bioavailability-enhanced formulations.
- **Optimized Liquid/Pellet Formulations**: Proprietary formulations with absorption enhancers achieved 97.64–97.74% dissolution within 15 minutes versus 10% for crude extract in 2 hours; these are preferable for maximum systemic exposure.
- **Traditional Decoction (Ayurveda/TCM)**: Dried aerial parts of Andrographis paniculata are decocted in water (3–9 g dried herb per day in TCM; kalamegh churna 1–3 g twice daily in Ayurveda), delivering andrographolide alongside neoandrographolide and other diterpenoids.
- **Bioavailability Note**: Natural oral bioavailability is poor (~1.19% in rats) due to high lipophilicity and extensive first-pass metabolism; co-administration with lipid-based carriers or piperine may improve absorption.
- **Timing**: Based on Tmax of 1.6 hours in humans, administration with meals may modulate absorption; twice-daily dosing aligns with the 10.5-hour half-life observed in human pharmacokinetic studies.

Synergy & Pairings

Andrographolide combined with piperine (from black pepper) may enhance oral bioavailability by inhibiting P-glycoprotein-mediated efflux and CYP3A4-mediated first-pass metabolism, a strategy documented for other poorly bioavailable phytochemicals and theoretically applicable given andrographolide's similarly low natural bioavailability of ~1.19%. In traditional Ayurvedic formulations, Andrographis paniculata is frequently co-administered with Tinospora cordifolia (guduchi) and Phyllanthus niruri, with the combination hypothesized to provide additive hepatoprotective and immunomodulatory effects through complementary NF-κB and oxidative stress pathway inhibition. Andrographolide's NF-κB inhibitory activity may synergize with omega-3 fatty acids (EPA/DHA), which suppress NF-κB through independent lipid mediator pathways (resolvins, protectins), representing a mechanistically rational anti-inflammatory stack.

Safety & Interactions

At doses used in the Phase I HIV trial, andrographolide appeared generally well-tolerated with an acceptable safety profile; however, cytotoxicity has been documented in human peripheral blood lymphocytes at concentrations above the immunostimulatory range of 1 µM, indicating a narrow therapeutic window that requires careful dosing. Known potential drug interactions include additive hypotensive effects with antihypertensive agents (given andrographolide's 94% ACE inhibition in vitro) and theoretical potentiation of anticoagulant or antiplatelet drugs through platelet aggregation inhibition pathways reported in preclinical data. Andrographolide is contraindicated in pregnancy due to preclinical evidence of uterine contractile activity and potential abortifacient effects; lactating women should also avoid supplementation pending adequate safety data. Hepatotoxic effects have not been reported at conventional doses, and the compound is traditionally regarded as hepatoprotective, but chronic high-dose exposure in rats resulted in rapid tissue accumulation particularly in the kidney (C_max 115.81 ng/mL), and the long-term safety implications of such tissue accumulation in humans have not been systematically studied.